Monte Rosa Therapeutics, Inc. Common Stock
GLUE US61225M1027
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Dunn Edmund CCO |
4.45 USD |
2,062 Sold |
9,174 USD |
03/06/2025 | 03/06/2025 |
| Dunn Edmund CCO |
4.45 USD |
2,062 Sold |
9,174 USD |
03/06/2025 | 03/06/2025 |
| Leo Chandra P. |
5.84 USD |
10,000 Bought |
58,383 USD |
24/03/2025 | 24/03/2025 |
| Dunn Edmund CCO |
3.83 USD |
1,610 Sold |
6,166 USD |
05/07/2024 | 05/07/2024 |
| Dunn Edmund CCO |
4.04 USD |
1,207 Sold |
4,876 USD |
03/06/2024 | 03/06/2024 |